Skip to main content
Delfa

← Trials/Trial dossier/NCT00522015

psp

UnknownPhase 2

Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy

Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study

Asset

Rivastigmine

Listed sites

1

Recruiting sites

1

Enrollment

20

estimated

Study population

Frontotemporal dementia

Key I/E criterion

•Age ≥50

Primary endpoint

•Improvement in neuropsychological assessments for memory

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

SecondaryeudraCT no: 2006-006166-42
NCT IDNCT00522015
Org study IDRIVA

Timeline

Milestones

Study first posted2007-08-29estimated
Study start2008-02 (month precision)
Last update posted2008-02-18estimated
Primary completion2009-12 (month precision)
Study completion2010-02 (month precision)

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Frontotemporal dementia

Eligibility

Who can enroll

Minimum age50 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•diagnosis of PSP
•willingness to participate in the study
•informed consent
•ability to speak
•no further CNS diseases
•written informed consent
•stable state of health
•ability to give informed consent, will checked by an independent physician

Exclusion criteria

•alcohol abuses
•acute psychosis
•pregnancy or lactation
•known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives
•liver failure
•known sick sinus syndrome or excitation disturbance
•known ulcus ventriculi or duodenal ulcer
•known asthma or COPD
•seizures
•renal failure

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Memory
1
Executive function / language
1

Memory

1 endpoint
Primary/protocol endpoint

improvement in neuropsychological assessments for memory and executive function, e.g. tested by "Tower of London Test, CERAD Battery and Logical Memory Test (WMSR)"

Time frame:6 month

change from baseline, improvement

Executive function / language

1 endpoint
Secondary/protocol endpoint

changes in speech function and improvement of quality of life

Time frame:6 Month

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.